Trabectedin

Oncologist

Volumn 14, Issue 8, 2009, Pages 794-799

  Chuk, Meredith K ^a   Balis, Frank M ^a   Fox, Elizabeth ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

DNA repair; Drug profile; Trabectedin

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BRCA1 PROTEIN; CISPLATIN; DEXAMETHASONE; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; KETOCONAZOLE; PACLITAXEL; TRABECTEDIN; TROLEANDOMYCIN;

AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TREATMENT FAILURE; FATIGUE; GENE EXPRESSION; HUMAN; LIVER TOXICITY; MULTIPLE CYCLE TREATMENT; MYXOSARCOMA; NAUSEA; OVARY CANCER; PHARMACOGENETICS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SIDE EFFECT; SOFT TISSUE SARCOMA; VOMITING;

ANTINEOPLASTIC AGENTS, ALKYLATING; DIOXOLES; HUMANS; TETRAHYDROISOQUINOLINES;

EID: 70249135331     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0104     Document Type: Review

References (61)

1. Martinez EJ, Corey EJ. A new, more efficient, and effective process for the synthesis of a key pentacyclic intermediate for production of ecteinascidin and phthalascidin antitumor agents. Org Lett 2000;2:993-996.
2. Garcia-Carbonero R, Supko JG, Manola J et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004;22:1480-1490. (Pubitemid 41103631)
3. Garcia-Carbonero R, Supko JG, Maki RG, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 2005;23:5484-5492. (Pubitemid 46300141)
4. Le Cesne A, Blay JY, Judson I et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005;23:576-584. [Erratum in: J Clin Oncol 2005;23:5276.] (Pubitemid 46224235)
5. Yovine A, Riofrio M, Blay JY et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004;22:890-899. (Pubitemid 41103601)
6. Grosso F, Jones RL, Demetri GD et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007;8:595-602. (Pubitemid 46995623)
7. Morgan JA, Le Cesne A, Chawla S et al. Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma (L-sarcomas) after failure of prior anthracyclines (A) and ifosfamide (I). J Clin Oncol (ASCO Annual Meeting Proceedings) 2007;(part 1)25(18S)(suppl):10060.
8. Krasner CN, McMeekin DS, Chan S et al. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 2007;97:1618-1624. (Pubitemid 350249358)
9. Zelek L, Yovine A, Brain E et al. A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer 2006;94:1610-1614. (Pubitemid 43924922)
10. Michaelson, D, J Bellmunt, N Lewis, et al., Phase II study of trabectedin in men with castration resistant prostate cancer (PRPC). ASCO-2009 Genitourinary Cancers Symposium Abstract 175, 2009.
11. Taamma A, Misset JL, Riofrio M et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol 2001;19:1256-1265. (Pubitemid 32202528)
12. Forni C, Minuzzo M, Virdis E et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther 2009;8:449-457.
13. Takahashi N, Li WW, Banerjee D, et al. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res 2001;7:3251-3257. (Pubitemid 32963850)
14. Meco D, Colombo T, Ubezio P et al. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother Pharmacol 2003;52:131-138. (Pubitemid 37041346)
15. D'Incalci M, Jimeno J. Preclinical and clinical results with the natural marine product ET-743. Expert Opin Investig Drugs 2003;12:1843-1853. (Pubitemid 37408131)
16. D'Incalci M, Colombo T, Ubezio P et al. The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer 2003;39:1920-1926. (Pubitemid 37311190)
17. Riccardi A, Meco D, Ubezio P et al. Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft. Anticancer Drugs 2005;16:811-815. (Pubitemid 41215745)
18. Messersmith WA, Jimeno A, Ettinger D et al. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol 2008;63:181-188.
19. Sessa C, Cresta S, Noberasco C et al. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours. Eur J Cancer 2009 [Epub ahead of print[.
20. Sessa C, Perotti A, Noberasco C et al. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur J Cancer 2009;45:1153-1161.
21. Blay JY, von Mehren M, Samuels BL et al. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Clin Cancer Res 2008;14:6656-6662.
22. von Mehren M, Schilder RJ, Cheng JD et al. A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann Oncol 2008;19:1802-1809.
23. Monk BJ, Herzog T, Kaye S, et al. A randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in relapsed, recurrent ovarian cancer (OC). Ann Oncol Presidential Symposium Abstract LBA4, 2008;19.
24. Lau L, Supko JG, Blaney S et al. A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study. Clin Cancer Res 2005;11:672-677.
25. Wood RD. Human diseases associated with defective DNA excision repair. J R Coll Physicians Lond 1991;25:300-303.
26. Hanawalt PC. Transcription-coupled repair and human disease. Science 1994;266:1957-1958.
27. Bohr VA, Brosh RM Jr, von Kobbe C, et al. Pathways defective in the human premature aging disease Werner syndrome. Biogerontology 2002;3:89-94. (Pubitemid 34284984)
28. Gillet LC, Scharer OD. Molecular mechanisms of mammalian global genome nucleotide excision repair. Chem Rev 2006;106:253-276. (Pubitemid 43316557)
29. Hanawalt PC, Spivak G. Transcription-coupled DNA repair: two decades of progress and surprises. Nat Rev Mol Cell Biol 2008;9:958-970.
30. Pommier Y, Kohlhagen G, Bailly C et al. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 1996;35:13303-13309. (Pubitemid 26349423)
31. Friedman D, Hu Z, Kolb EA, et al. Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res 2002;62:3377-3381. (Pubitemid 34651382)
32. Jin S, Gorfajn B, Faircloth G, et al. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci U S A 2000;97:6775-6779. (Pubitemid 30412790)
33. Minuzzo M, Marchini S, Broggini M et al. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci U S A 2000;97:6780-6784. (Pubitemid 30412791)
34. Erba E, Bergamaschi D, Bassano L et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 2001;37:97-105. (Pubitemid 32119366)
35. Takebayashi Y, Pourquier P, Zimonjic DB et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001;7:961-966. (Pubitemid 32756435)
36. Damia G, Silvestri S, Carrassa L, et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 2001;92:583-588. (Pubitemid 32319434)
37. Tavecchio M, Simone M, Erba E et al. Role of homologous recombination in trabectedin-induced DNA damage. Eur J Cancer 2008;44:609-618.
38. Soares DG, Escargueil AE, Poindessous V et al. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci U S A 2007;104:13062-13067. (Pubitemid 351737593)
39. Herrero AB, Martin-Castellanos C, Marco E et al. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 2006;66:8155-8162. (Pubitemid 44299183)
40. Grosso F, Dileo P, Sanfilippo R et al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer. 2006;42:1484-1490. (Pubitemid 43903160)
41. Beumer JH, Schellens JH, Beijnen JH. Hepatotoxicity and metabolism of trabectedin: a literature review. Pharmacol Res 2005;51:391-398. (Pubitemid 40321008)
42. Yver A, Cohen R, Williams D et al. Assessment of trabectedin (T) induced liver toxicity with correlation to liver morphology in a phase I study of T + pegylated liposomal doxorubicin (PLD). J Clin Oncol (ASCO Annual Meeting Proceedings) 2006;(part 1)24(18S)(suppl):9568.
43. Puchalski TA, Ryan DP, Garcia-Carbonero R et al. Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol 2002;50:309-319.
44. Schoffski P, Wolter P, Clement P, et al. Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma. Future Oncol 2007;3:381-392. (Pubitemid 47250154)
45. Stokvis E, Rosing H, Lopez-Lazaro L et al. Simple and sensitive liquid chromatographic quantitative analysis of the novel marine anticancer drug Yondelis (ET-743, trabectedin) in human plasma using column switching and tandem mass spectrometric detection. J Mass Spectrom 2004;39:431-436. (Pubitemid 38515357)
46. Beumer JH, Lopez-Lazaro L, Schellens JH et al. Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743). Curr Clin Pharmacol 2009;4:38-42.
47. Brandon EF, Sparidans RW, Guijt KJ et al. In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs 2006;24:3-14.
48. Vermeir M, Hemeryck A, Cuyckens F et al. In vitro studies on the metabolism of trabectedin (YONDELIS) in monkey and man, including human CYP reaction phenotyping. Biochem Pharmacol 2009;77:1642-1654.
49. Beumer JH, Rademaker-Lakhai JM, Rosing H et al. Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer. Cancer Chemother Pharmacol 2007;59:825-837. (Pubitemid 46440606)
50. Perez-Ruixo JJ, Zannikos P, Hirankarn S et al. Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients. Clin Pharmacokinet 2007;46:867-884. (Pubitemid 47443311)
51. European Medicines Agency (EMEA). Trabectedin 2007. Available from: Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/yondelis/H-773-en6. pdf. Accessed June 30, 2009.
52. Salazar R, Pardo B, Majem M et al. Phase I clinical and pharmacological trial of trabectedin (T) in 3 hour infusion every 3 weeks (3h/q3w) in patients with advanced cancer and hepatic function disorder. American Society of Clinical Oncology (ASCO) Annual Meeting 2006;24:2080.
53. Schoffski P, Grosso F, Taron M et al. DNA repair functionality as a molecular signature for sensitivity (S)/resistance (R) in sarcoma patients (pts) treated with trabectedin (ET-743, Yondelis). AACR Annual Meeting, Abstract #144, Los Angeles April 2007, 200.
54. Rosell R, Grosso F, Schoffski P et al. DNA repair efficiency as a model for personalized therapy with trabectedin. Second AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development, Abstract C127, SanFrancisco, CA. October 2007, 2007.
55. Tercero JC, Jimeno J, Martinez N et al. Predicting sarcoma-patients response to trabectedin treatment with molecular markers detected by immunohistochemistry. AACR-International Conference on Molecular Diagnostics in Cancer Therapeutic Development Abstract B8, September 2008, Philadelphia, 2008.
56. Rosell R, Martinez N, Rodriguez S et al. Expression of XPG mRNA and protein as potential biomarker of response to trabectedin in sarcoma patients. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Abstract C127, San Francisco, CA, October 2007, 2007.
57. Manara MC, Perdichizzi S, Serra M et al. The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71. Int J Oncol 2005;27:1605-1616.
58. Beumer JH, Buckle T, Ouwehand M et al. Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype. Invest New Drugs 2007;25:1-7. (Pubitemid 44657637)
59. Hing J, Perez-Ruixo JJ, Stuyckens K et al. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia. Clin Pharmacol Ther 2008;83:130-143.
60. van Kesteren C, Cvitkovic E, Taamma A et al. Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. Clin Cancer Res 2000;6:4725-4732. (Pubitemid 32110411)
61. Fetterly GJ, Owen JS, Stuyckens K et al. Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment. Cancer Chemother Pharmacol 2008;62:135-147. (Pubitemid 351537854)